December 5, 2002
AmeriPath Acquires Wisconsin Dermatopathology Laboratory
-Expands Presence in Midwest Region -

Riviera Beach, FL, December 5, 2002 – AmeriPath, Inc. (Nasdaq: PATH), a leading national provider of cancer diagnostics, genomic, and related information services, today announced the acquisition of Dermatopathology of Wisconsin, an independent dermatopathology laboratory located in Brookfield, Wisconsin, a western suburb of Milwaukee.

Dermatopathology of Wisconsin provides dermatopathology services to dermatologists and other physicians across Wisconsin. Through his practice and through his academic relationships, Dr. James L. Troy, the founder of Dermatopathology of Wisconsin, has established an excellent reputation within his community. Dermatopathology of Wisconsin was established as an independent laboratory 13 years ago. Dermatopathology of Wisconsin employs a staff of 12, including two Dermatopathologists.

James C. New, Chairman and Chief Executive Officer commented, “Dr. Troy and his staff have an outstanding reputation of providing reliable accurate service and will contribute to our rapidly growing base of business in the Midwest region. Dermatopathology of Wisconsin is a solid platform for expansion into other Dermatopathology markets in the Midwest region and nationally. Our relationship with Dr. Troy and Dermatopathology of Wisconsin further enhances our standing as the leading provider of Dermatopathology services in the country.”

AmeriPath is a leading national provider of cancer diagnostics, genomics, and related information services. The Company’s extensive diagnostics infrastructure includes the Center for Advanced Diagnostics (CAD), a division of AmeriPath. CAD provides specialized diagnostic testing and information services including Fluorescence In-Situ Hybridization (FISH), Flow Cytometry, DNA Analysis, Polymerase Chain Reaction (PCRTM, performed pursuant to an agreement with Roche Molecular Systems, Inc.), Molecular Genetics, Cytogenetics and HPV Typing. Additionally, AmeriPath provides clinical trial and research development support to firms involved in developing new cancer and genomic diagnostics and therapeutics.

.........................................................................................................

The statements contained in this press release include "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements - which are sometimes identified by words such as "may", "should", "believe'', "expect'', "anticipate'', "estimate" and similar expressions and which include any financial or operating estimates, forecasts or projections - are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. These risks and uncertainties could cause actual results to differ materially from results anticipated by forward-looking statements. These risks and uncertainties include: the extent of success of the Company's operating initiatives and growth strategies; ability to manage growth; access to capital on satisfactory terms; general economic conditions; terrorism or an escalation of hostilities or war; competition and changes in competitive factors; federal and state healthcare regulation (and compliance); reimbursement rates under government and third party healthcare programs and the payments received under such programs; changes in coding; changes in technology; dependence upon pathologists and customer contracts; the ability to attract, motivate, and retain pathologists; labor, technology and insurance costs; marketing and promotional efforts; the availability of pathology practices in appropriate locations that the Company is able to acquire on suitable terms or develop; and the successful completion and integration of acquisitions (and achievement of planned or expected synergies). The forward-looking statements in this press release are made as of the date hereof based on management's current beliefs and expectations, and the Company undertakes no obligation to update or revise any such statements. Further information regarding risks, uncertainties and other factors that could affect the Company's financial or operating results or that could cause actual results to differ materially from those expected, estimated or anticipated are included in the Company's annual, quarterly, and other reports and filings with the SEC.